HyoSookHanMD

Breast Cancer

Physician

Overview of Dr. Han

Dr. Hyo Han is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from Seoul National University College of Medicine and has been in practice 18 years. She is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 60 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(563) 362-9232

Education & Training

Cleveland Clinic FoundationResidency, Internal Medicine, 2002 - 2005
Seoul National University College of MedicineClass of 1999

Certifications & Licensure

FL State Medical License 2008 - 2026
CA State Medical License 2004 - 2022
OH State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients Start of enrollment: 2013 Feb 06
Completed
Phase 1
COGNUTRIN in Breast Cancer Survivors Start of enrollment: 2014 Jul 30
Completed
Early Phase 1
Yoga for Aromatase Inhibitor-associated Joint Pain Start of enrollment: 2013 Sep 01
Completed
Not Applicable
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Start of enrollment: 2014 Sep 05
Completed
Phase 1, Phase 2
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

11 citations
A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2 + breast cancer
Ricardo Costa, Saif Zaman, Susan C. Sharpe, Irene Helenowski, Colleen Shaw
Drug Design, Development and Therapy. 2019-01-14
45 citations
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer
Hyo Sook Han, Isildinha M. Reis, Wei Zhao, Katsumasa Kuroi, Masakazu Toi
European Journal of Cancer. 2011-11-01
3 citations
Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar.
Suzanne C. O'Neill, Susan T. Vadaparampil, Richard L. Street, Tanina Foster Moore, Claudine Isaacs
Patient Education and Counseling. 2021-02-01

Lectures

SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresect...
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Vaccinex and Its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of CancerNovember 10th, 2022